Marrow Transplantation (EGBMT) criteria. 32 In 2 phase I/II clinical trials evaluating an RHAMM peptide vaccine in patients with acute myeloid leukemia, myelodysplastic syndromes, and multiple myeloma, a total of 7 patients with multiple myeloma were
Search Results
Role of Immune Therapies for Myeloma
Jacalyn Rosenblatt and David Avigan
Myeloid Growth Factors
Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt, and Michael Westmoreland
-macrophage CSF (GM-CSFs), is limited to use after induction therapy for acute myeloid leukemia (AML) and in various stem cell transplantation settings. Recommendations are based on evidence derived mainly from studies on G-CSFs; head-to-head comparative studies
Understanding Causes of Inferior Outcomes in Adolescents and Young Adults With Cancer
Julie A. Wolfson, Kelly M. Kenzik, Blake Foxworthy, John M. Salsman, Katherine Donahue, Marie Nelson, Mary Beth Littrell, Grant R. Williams, and Jennifer M. Levine
, including acute lymphocytic leukemia (ALL), Hodgkin and non-Hodgkin lymphoma, acute myeloid leukemia, central nervous system (CNS) tumors, and colorectal cancer. 11 – 15 There is a complex (and not yet fully understood) interplay between race
Myeloid Growth Factors
Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer, and Maria Ho
-macrophage colony stimulating factor (GM-CSF), is limited to use after induction therapy for acute myeloid leukemia and in various stem cell transplantation settings. It should be noted that recommendations are based on evidence derived mainly from studies on G
Imatinib Treatment of Lymphangiomatosis (Generalized Lymphatic Anomaly)
Laura J. Libby, Navneet Narula, Helen Fernandes, James F. Gruden, David J. Wolf, and Daniel M. Libby
gene are frequently reported in familial and multiple GIST, 13 familial mastocytosis, 14 and aggressive fibromatosis. 15 Multiple activating KIT mutations in exons 9, 11, 13, and 17 have been described in GIST, melanoma, acute myeloid leukemia, and
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management
Prithviraj Bose and Srdan Verstovsek
54 patients with post-MPN MDS or acute myeloid leukemia, azacitidine produced an overall response rate of 52% with a median response duration of 9 months and median overall survival of 11 months. 75 Decitabine also appears active in patients with
Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms
Amy E. DeZern and Peter L. Greenberg
continues the clinical and biologic rationale to maintain the 20% blast threshold for acute myeloid leukemia (AML). In contrast, a newer term, MDS/AML , was adopted by the ICC 4 as well as the European Leukemia Network 8 to denote myeloid neoplasms with
Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Point
Antonio V. Gonzalez, Andrew J. Ullmann, Nikolaos G. Almyroudis, and Brahm H. Segal
fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group . Cancer 1998 ; 83
A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications
Sanjeev Kumar Gupta, Nitin Jain, Guilin Tang, Andrew Futreal, Sa A. Wang, Joseph D. Khoury, Richard K. Yang, Hong Fang, Keyur P. Patel, Rajyalakshmi Luthra, Mark Routbort, Bedia A. Barkoh, Wei Chen, Xizeng Mao, Jianhua Zhang, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos, and Sanam Loghavi
with hypereosinophilia . Am J Hematol 2018 ; 93 : 1337 – 1346 . 30105844 10.1002/ajh.25247 10. Shah S , Loghavi S , Garcia-Manero G , . Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia
New Biosimilar Approvals for Myeloid Growth Factors and Anemia
Gary H. Lyman
transplant, of nonmyeloid malignancies (eg, acute myeloid leukemia), of severe chronic neutropenia, and for progenitor cell mobilization or collection. Concerns About Biosimilars Beyond data presented to the FDA, biosimilars are subject to variability and